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Transplantation is the preferred treatment for most end-stage solid organ diseases. Despite
potent immunosuppressive agents, chronic rejection remains a real problem in transplan-
tation. For many years, the predominant immunological focus of research into transplant
rejection has been T cells. The pillar of immunotherapy in clinical practice is T cell-directed,
which efficiently prevents acute T cell-mediated allograft rejection. However, the root of
late allograft failure is chronic rejection and the humoral arm of the immune response
now emerges as an important factor in transplantation. Thus, the potential effects of Abs
and B cell infiltrate on transplants have cast B cells as major actors in late graft rejection.
Consequently, a number of recent drugs target either B cells or plasma cells. However,
immunotherapies, such as the anti-CD20 B cell-depleting antibody, can generate deleteri-
ous effects on the transplant, likely due to the deletion of beneficial population.The positive
contribution of regulatory B (Breg) cells or B10 cells has been reported in the case of trans-
plantation, mainly in mice models and highlights the primordial role that some populations
of B cells can play in graft tolerance. Yet, this regulatory aspect remains poorly character-
ized in clinical transplantation. Thus, total B cell depletion treatments should be avoided
and novel approaches should be considered that manipulate the different B cell subsets.
This article provides an overview of the current knowledge on the link between Breg cells
and grafts, and reports a number of data advising Breg cells as a new target for future
therapeutic approaches.
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B CELLS’ DUAL ROLES IN TRANSPLANTATION
ROLE OF B CELLS IN ALLOGRAFT REJECTION
In acute rejection
Key advances in transplant rejection and tolerance came from
animal models and proved to be of great importance for sub-
sequent breakthroughs in transplant immunology. In acute rejec-
tion, antigen presentation through allorecognition plays a dom-
inant role in initiating the adaptive immune presentation to a
CMH-mismatched transplant. Subsequently to allorecognition,
a second essential signal is provided by the interaction of cos-
timulatory molecules with their ligands. Thus, B cells can inter-
act with T cells through the CMH-II and B7 family molecules,
leading to B and T cell co-activation, differentiation, and anti-
body (Ab) production. Then, B cells take part into the rejection
process by presenting antigens to T cells and by producing donor-
specific Abs (1). Costimulatory molecules play a major role in
this allorecognition. CD80 and CD86 molecules as well as the
inducible costimulatory (ICOS) protein, constitutively expressed
on B cells, interact with CD28 on T cells and induce activation
and expansion of alloreactive T cells in vitro (2). The produc-
tion of donor-specific alloAbs (DSA) represents another line of
evidence of the B cell contribution in acute rejection. Through
the generation of opsonized donor cells, B cells enhance T cell
alloimmune response and contribute to cellular rejection in a
model of skin allograft (3). In this study, the authors demonstrated
that polyclonal graft-reactive Abs in the sera of pre-sensitized mice
prevented long-term skin graft acceptance in recipients due to the
recruitment of complement proteins leading to humoral rejec-
tion. Although advances on transplant rejection understanding
from animals models are hardly substitutable to humans. Never-
theless B cells have been observed in pediatric biopsy samples (4,
5). These data clearly demonstrated the presence of dense CD20
staining in approximately one third of the 52 biopsy samples
from patients with acute rejection and was significantly associ-
ated with glucocorticoid resistance and eventual graft failure. In
association with molecular analysis of the biopsy profile, it has
been demonstrated a strong correlation between CD20+ lym-
phoid aggregates and poor graft outcomes in acute rejection.
The presence of B cells infiltrating allografts has been further
confirmed in a 4-year follow-up study and found to be asso-
ciated with reduced graft survival (6). The nature of intragraft
B cells has been then explored through immunohistochemical
analysis. Cluster-forming CD20+ B cells in the rejected grafts
are activated and present MHC Class II antigen (HLADR+) to
CD4+ T cells. Some of these clusters contain memory B cells
(CD27+) (5).
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In chronic rejection
Acute rejection episodes appear to increase the risks of chronic
graft failure development, which is the major complication for
long-term allograft survival in humans (7). Indeed, chronic allo-
graft dysfunction in solid transplantation is the principal cause
of morbidity and of late allograft loss. A recent evaluation of
the short- and long-term renal allograft survival evolution in the
United States over 20 years has shown a significant improvement
in short-term graft and patient survivals. However, the long-term
attrition rates have been slightly improved in spite of arguably
more high-risk patients now reaching at least the 1-year mark (8).
While, increased immunosuppression has lowered acute rejection
rates, it led to more graft loss driven by opportunistic infections or
over-immunosuppression (9). Thus, chronic dysfunction remains
a universal phenomenon, and not only in the United States (10).
Atherosclerosis is defined as a hallmark of chronic allograft dys-
function. The obstruction of the arterial results in ischemia and
subsequently in graft loss (11). In an aortic graft mouse model,
Wood et al. showed that transplant atherosclerosis does not occur
in the absence of the adaptive immune system (12). When allore-
active T cells and B cells are present, transplant vasculopathy is
detectable within 30 days of transplantation. Furthermore, local
regulation of the destructive immune effectors may be induced
by the transfer of ex vivo expanded regulatory T (Treg) cells, sug-
gesting that the regulation of the alloimmune response could be
impaired in chronic dysfunction (13). Furthermore alloAb pro-
duction has been demonstrated in human renal transplantation
and was found to be predictive of transplant failure (14). Germinal
center formation has been described in chronically rejected human
heart and kidney, supporting the development of a humoral local
immune response (15). In cardiac allograft rejection, infiltration
of B cells was also correlated with a higher risk of chronicity of
graft failure (16). Altogether, these works clearly suggest that B
cells could play pathogenic roles in the course of graft loss.
ROLE OF B CELLS IN GRAFT TOLERANCE
Considering the overall immunosuppressive function of regu-
latory B (Breg) cells, particularly in autoimmunity (17), the B
cell-mediated alloimmune response could also play a critical role
in graft acceptance in transplantation. Experiments with rodent
models indicate an accumulation of B cells in tolerant allografts
and the formation of germinal centers in transplants with an
inhibitory profile (18). In humans, the proportions of whole
B cells are increased in transplant-tolerant patients but not in
patients under immunosuppressive treatment (19). Furthermore,
an increased frequency of the IL-10+CD24+CD38high immature
Breg cells has been observed in tolerant renal-transplanted patients
(20). Using microarray approach, the authors demonstrated a mol-
ecular signature of tolerance associated with B-cell specific genes.
Although this signature may be the consequence of tolerance and
not the cause, the authors suggested that B cells could be the pri-
mary drivers of the tolerant state. This hypothesis challenges the
prevailing paradigm that Treg cells are the principal mediators of
transplantation tolerance, and is consistent with emerging data on
the role of Breg cells in other immune processes. In line with these
observations, large numbers of regulatory CD19+CD5+CD1d+ B
cells have been observed in the peripheral blood of patients with
long-term kidney graft function (21). In this study, the authors
showed that B cells overexpressed the negative B cell receptor
FcγRIIb and the negative transcriptional regulator Bank. More-
over, in another group of tolerant patients, peripheral B cells
conserved a high capacity to activate the CD40/STAT3 signaling
pathway, which promotes high level of IL-10 secretion (22); IL-
10 secretion being likely involved in their regulatory activity (23).
These results indicate that tolerant patients exhibit B cells with an
inhibitory profile, and that some B cell subsets could play a central
role in the transplant survey. However, tolerance initiation may
be more complicated. Indeed, the depletion of B cells from the
PBMC of two patients with high naive B cell counts (one tolerant
and one who had received standard immunosuppression) has no
effect on the strong, indirect pathway used by T cell regulation
(24). The authors propose hypothetical models in which a strictly
regulated equilibrium exists between tolerance and rejection. In
the conditions of chronic rejection, T cells are less constrained by
Treg cells, and cellular immunity is joined by humoral immunity
to activate germinal centers’ B cells in order for them to differ-
entiate into DSA-secreting plasma cells. In the state of tolerance,
there are critical factors that maintain high levels of regulation
in a tissue-specific manner (25). These factors could reside in the
increased numbers of circulating B cells, possibly including Breg
cells, and the accumulation of Breg cells in the graft.
REGULATORY B CELLS IN MICE AND HUMANS
B10 IN MOUSE
B10 phenotype
B cells are generally seen as important regulators of the immune
responses due to their effector roles giving rise to Ab-producing
plasma cells, because they are critical APC that facilitate CD4+
T cell activation, and effect multiple other roles in the immune
function (26). Nonetheless, the role of B cells in immune systems
extends beyond the production of Abs and their Ag-presenting
capacities. Over the past decade, novel B cell regulation has
been demonstrated in multiple mouse models. The first evidence
appeared in 1996 in EAE. Wolf et al. demonstrated that B cells
have an incidence in the immune regulation over the course of
the disease and contribute to spontaneous recovery (27). B cell-
mediated regulation has been further established in intestinal
chronic inflammation disease (IBD), collagen-induced arthritis
(CIA), and asthma (27–31). Although the identification of dif-
ferent B cell subsets with regulatory functions and the definition
of their mechanisms of action are recent events, IL-10-producing
Breg cells called B10 cells are the most widely studied Breg cell
subset (32).
Numerous studies report contradictory phenotypes of this
subpopulation and various B10 profiles have been described in
mouse models of autoimmunity. Only a small portion of B
cells (1–3% of splenic B cells in wild-type C57Bl6 mice) pro-
duced IL-10 after PMA and ionomycin stimulation, implying that
not all B cells are able to produce IL-10 (33). The intracellular
detection of IL-10 combined with flow cytometric phenotyping
have shown that mouse spleen B10 cells are enriched within the
small CD1dhighCD5+ B cell subset, where they represent 10–
20% of the cells in C57Bl6 mice. This phenotypically unique
CD1dhighCD5+ B cell population shares overlapping cell surface
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markers with a variety of phenotypically defined subsets such
as CD5+ B1a B cells, CD1dhighCD23−IgMhigh marginal zone B
cells, and CD21highCD24high transitional type 2-marginal zone
precursor B cells. The production of IL-10 can be attributed to the
CD19+CD21highCD23highIgMhigh transitional B cell subset in the
peripheral blood of experimental arthritis (34). The plasticity of
IL-10 production makes its usage very difficult as a single marker
for B10 cells and depends, in a critical fashion, upon the phys-
iopathological models (resumed in Table 1). Indeed, the functional
identification of IL-10-producing B cells may not be restricted to
a unique B cell subset and may be a hallmark of an inflammatory
micro-environment.
B10 development
The intracellular detection of IL-10 in B cells can be performed
both in vivo and in vitro, in response to various stimuli, which
would suggest that IL-10-mediated regulation can be acquired in
physiological environments. In an islet allograft rejection model,
Breg cells are induced by T cell Ig and mucin domain (TIM)
protein-1. They can transfer long-term acceptance in recipients
in an IL-10-dependent fashion (40). CD40 engagement appears
to be required for the IL-10-dependent Breg cell function in EAE
and CIA (29, 36). In transplantation mouse models, allograft toler-
ance is generated by the administration of anti-CD45RB Ab and is
achieved when CD45RB-expressing B cells are present. The induc-
tion of tolerance requires that B cell express B7,CD40,and ICAM-1
molecules, suggesting that the B cell-mediated regulatory function
is dependent on direct T cell-to-B cell contacts (51). Moreover, sev-
eral publications emphasize the role of Toll-like receptors (TLR) in
B cell-mediated regulation. Mice lacking MyD88, TLR2, or TLR4
exclusively on B cells, develop a chronic EAE (52). CpG (a TLR-9
ligand) can upregulate the production of IL-10 from B cells (53).
Thereby, in mice with lupus-like autoimmune disease, splenic B
cells with a CD1highCD23−marginal zone phenotype can produce
IL-10 in response to CpG stimulation (54).
Another key component in the mouse Breg function is the
signalings via the BCR. The percentage of Breg was found to
have decreased by 90% in MD4 mice with a fixed BCR specific
for hen egg lysozyme. Conversely, the overexpression of CD19
and the increased CD40L signaling resulted in an increased num-
ber of B10 cells in transgenic mice (55). CD22-/- mice that also
ectopically express CD40L show dramatically enhanced num-
bers of CD1dhighCD5+ B and B10 cells (56). The importance
of BCR-related signals is further emphasized by the analysis of
the stromal interaction molecules (STIM) 1 and 2. Remarkably, B
cells lacking both STIM proteins failed to produce IL-10 after BCR
stimulation (31).
More recently, IL-21 has been shown to cause a dramatic
increase in the Breg cells frequency and an augmentation of IL-10
secretion (57). These data served to demonstrate that the regula-
tory B10 cell function requires IL-10 expression, IL-21R signaling
as well as CD40, and MHC-II interactions. Finally, it was observed
that IL-21 promotes the production of IL-10 and Granzyme B by
Breg cells in solid tumor infiltrates (49).
Although IL-10 generally plays immunosuppressive roles dur-
ing inflammation, IL-10 has also pleiotropic and immunos-
timulatory activities that opacify the precise role of B10 cells
Table 1 | Immunophenotype of the regulatory B cells identified in
mouse models and human pathologies.
Phenotype Model/pathology Reference
Mouse None EAE (27)
None Chronic colitis (35)
CD1dhigh Chronic colitis (29)
CD19high CIA (36)
CD21highCD23low CHS (37)
CD21highCD23high CIA (34)
CD1dhighCD5+CD19high CHS (38)
CD1hihCD5−CD11b+IgMhigh Chronic colitis (39)
Tim-1+CD5+ Islet allograft (40)
CD19highCD32bhigh OVA-TCR Tg (41)
CD19+CD5+CD1d+ Pregnancy model
of tolerance
(42)
CX3CR1+ Allergy-induced
inflammation
(43)
Human CD24highCD38high SLE (23)
CD24highCD27+ Autoimmunity (44)
CD5+CD24+IgD+CD38+ SLE (45)
CD24highCD38high ITP (46)
CD19+CD24highCD27+ Graves’ disease (47)
CD48+CD148+ Autoimmunity (48)
CD19+CD38+CD147+IgM+ Cancer (49)
CD73−CD25+CD71+ Allergy (50)
EAE, experimental autoimmune encephalomyelitis; CIA, collagen-induced arthri-
tis; CHS, contact hypersensitivity; OVA, ovalbumin; TCR, T cell receptor; SLE,
systemic lupus erythematosus; ITP, idiopathic thrombocytopenic purpura.
during immune responses. IL-10 represents a key cytokine in
Th2-mediated immunity and may be involved in chronic allo-
graft rejection in mice. In a fully mismatched heterotopic mouse
heart transplantation model, T-bet and RORγt double-deficient T
cells differentiated into alloreactive GATA-3-expressing Th2 cells,
which promptly induced allograft rejection characterized by a
Th2-type intragraft expression profile (58).
HUMAN BREGS
All these observations emphasize the importance of B10 cells in
mice. The existence of B10 in humans remains unclear and is
currently difficult to unify in a coherent model (Table 1). An
orthologous IL-10-producing B cell has been described in the
CD24highCD38high transitional B cell subset (23, 59). Interestingly,
this population displays regulatory capacities in healthy volun-
teers, manifested by the suppression of the Th1 cell differentia-
tion that appears deficient in systemic lupus erythematosus (SLE)
patients. Such a defective function of Breg cells could take part into
the severity of autoimmune disorders (60). Conversely, SLE B cells
spontaneously produced more cytoplasmic IL-10 than control B
cells (61). Furthermore, IL-10 can also promote humoral immu-
nity. Human tonsillar B cells co-cultured with CD154-expressing
fibroblast secrete large amounts of IL-10, and blockade of the
IL-10 function suppress Ig release in a concentration-dependent
manner (62). Interestingly, human T cells can activate B cells
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following CD40L/CD40 interaction and develop their regulatory
functions, which are highlighted by an IL-10-independent sup-
pressive effect on T cell proliferation and by the generation of
Treg cells (45). More recently, Iwata et al. demonstrated the exis-
tence of human IL-10-competent B10 cells noticeable for their
ability to secrete IL-10 after in vitro stimulation (44). These
B10pro B cells were predominantly CD24highCD27+ and specifi-
cally influence the innate monocyte function. Interestingly, both
CD24highCD27+ and CD24lowCD27− B cells reduced the expres-
sion of Th1 cytokine by T cells through an IL-10-independent
pathway. Altogether, these evidences demonstrate that human Breg
cells may exist beyond IL-10 secretion exclusively. Their precise
phenotype and functional capacity need to be further defined and
could be critically dependent on the pathology. Furthermore, it
could be surmised that B cell-mediated regulation is not restricted
to one unique B cell subset but could be triggered by different
subset of B cells in association with the physiological contexts.
Several studies have shown that the functional action of Breg
cells in human-transplant patients remains ill-defined, and clear
identification of the Breg cell subsets is still arduous. A common
approach for studying human B cell regulation rely on the analy-
sis of phenotypic transitional B cell subsets in peripheral blood.
Although this population is increased in tolerant patients (20,
63) and in kidney transplant recipients with an excellent long-
term graft function under immunosuppression (63), no functional
data exist that involve Breg populations in the control of the
alloimmune response in patients. We recently developed an novel
approach to study human B cell regulation. This model led us
the possibility to analyze the B cell-mediated suppression of both
T cell proliferation and Th1 differentiation in auto- and heterol-
ogous cocultures regardless of the phenotype (64). These data
demonstrate that Ab-mediated chronic rejection is associated with
a defective B cell regulatory function. Furthermore, we posit that,
when activated, B cells could have different regulatory capacities
based on their maturation status. Discrepancies in the descrip-
tion of homogenous Breg subsets lead us to the conclusion that B
cells are able to exhibit functional plasticity that relies on immune
regulatory processes to favor either immunity or tolerance.
B CELL-MEDIATED REGULATION IS NOT EXCLUSIVELY DEPENDENT ON
IL-10
It becomes clear that, in addition to IL-10 production, B cells
are able to regulate immune responses through other regulatory
processes. Granzyme B, an enzymatic component of the cytotoxic
granules, can be produced by B cells. It mediates the cleavage of cas-
pases and initiates the apoptosis of human-infected cells (65). The
expression of death-inducing ligands is another B cell-dependent
regulatory mechanism. Thus, Fas ligand (FasL) and tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL) expressed on
mouse and human B cells are able to activate programed cell death
in target cells, following ligation with their cell surface receptor
(66). Programed death ligand (PD-L) 1 and 2 have also been
reported to be expressed by B cells. They can participate in B cell
immune suppression. All these data demonstrate that direct cellu-
lar contacts without soluble factor are important components for
Breg cell activity. Moreover, in mouse EAE model, B cell can regu-
late CD4+CD25+ Treg cell expansion via B7 expression, resulting
in the suppression of autoimmune inflammation and recovery
(67). It seems that human Breg cells have a similar faculty to
expand CD4+CD25+Foxp3+ Treg cells and to contribute to the
regulation of the Th1 immune response (45). Besides IL-10 secre-
tion, other B cell-secreted soluble factors support this regulatory
mechanism. For example, the production of TGFβ can lead to the
induction of Foxp3+ Treg cells, and thereby, contribute to exert
immune suppressive function. In vitro experiments using a murine
model of allergic airway disease, demonstrated that B cell-secreted
TGFβ was involved in the downregulation of lung inflammation
and asthma in recipient ovalbumin-sensitized mice after adoptive
transfer. Furthermore, TGFβ-expressing B cells induced the con-
version of CD4+CD25− effector T cells into CD4+CD25+Foxp3+
Treg cells (68). Overall, the immunosuppressive actions of the Breg
cells appear complex (69) and cannot be confined only to the secre-
tion of IL-10. Rather, they result from a combined mechanism that
associates several cytokines and different cell-to-cell contacts.
Besides, B cells have been shown to secrete natural Abs with
immunosuppressive functions in both normal and pathological
situations. These Abs can bind to the surface of apoptotic cells. As
a result, the phagocytosis efficiency of macrophages and dendritic
cells is increased (70). Moreover, these Abs are able to negatively
regulate the inflammatory capacity of APC, due to the inhibi-
tion of the dendritic cells maturation and the downregulation of
molecules involved in antigen presentation (71). The production
of Ig appears to be a powerful tool for the control of inflamma-
tion. Studies about IVIg clearly demonstrated that a small fraction
enriched for a glycoform of IgG possessing sialic acid displayed
anti-inflammatory activity in mouse models (72) and in humans
(73). The IgG sialylation status may prove to be an important fac-
tor in the disease course of alloreactivity. In mouse experiments,
T cell-independent immune responses induced suppressive sia-
lylated IgGs, in contrast to T cell-dependent proinflammatory
Th1 and Th17 immune responses that induced agalactosylated
and asialylated IgGs. Interestingly, the transfer of low amounts of
antigen-specific sialylated IgG Abs was sufficient to inhibit B cell
activation and pathogenic immune reactions (74). Further studies
need to be performed to clarify the nature of alloAbs in models of
allograft tolerance and in humoral chronic rejection in humans.
B CELL-BASED THERAPEUTICS
Currently, various drugs targeting T cells are efficiently used to
prevent acute rejection in transplantation. However, the efficacy of
these treatments is less convincing in chronic dysfunction. A large
number of therapeutic options that modify B cell responses are
being developed in order to induce tolerance. This useful approach
consists in depleting B cells to reduce their possible contribution
in alloimmune responses. Numerous cytotoxic Abs binding to B
cell surface expressed antigens are available. For example, the anti-
CD52 monoclonal Ab Alemtuzumab, is known to prevent acute
rejection by depleting T cells and B cells, even though it increases
the incidence of humoral rejection in chronic rejection (75). Ritux-
imab (RTX) is a chimeric monoclonal Ab directed toward the pan
B-cell surface molecule CD20. It has been shown in some studies
that RTX could prevent the emergence of alloAb-producing cells
and eliminate short-lived plasma cells; and thereby prove to be
clinically effective in the treatment of acute rejection (76).
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Nowadays, the involvement of B cells in tolerance might
compromise therapeutics targeting B cells Treatment with anti-
thymocyte/lymphocyte globulins (ATG) is another approach used
to deplete B cells but also T cells and natural killers (NK).
ATG induce persistent changes in T cell subsets characterized
by low CD4 counts, but they also have deleterious effects on
B cell numbers. Interestingly, lymphopenia promotes accelerated
atherosclerosis and increases the risk of post-transplantation mor-
bidity (77). The authors suggested that ATG could accelerate
immune system aging, characterized by CD4 T cell lymphopenia,
CD8 expansion, reduced B cell numbers, and high levels of acute-
phase response proteins. This immunosenescence may accelerate
rejection. How the decrease of B cells is involved in this process
remains to be determined.
Recently, increased levels of B cell activating factor (BAFF) in
transplant rejection have been underlined, suggesting a distinct
way for therapeutics in transplantation. Indeed, high BAFF-R
and BAFF levels are correlated with higher risks of developing
graft dysfunction and DSA in stable patients (78) and are associ-
ated with increased risks of Ab-mediated rejection (79). Thus,
blockade of the BAFF- and APRIL-dependent stimulations of
B cells using Atacicept (a recombinant TACI-Ig fusion protein)
or Belimumab (a human anti-BAFF monoclonal Ab) could be
promising. Indeed, Atacicept can prevent B cell maturation, dif-
ferentiation, and survival while Belimumab can bind and inhibit
soluble BAFF (80).
Despite a growing number of drugs used in transplantation,
humoral chronic dysfunction is still a recurrent problem mainly
because the precise role of B cells has yet to be completely deci-
phered. One of the main problems lies in the ability to discriminate
regulatory and effector B cells involved in the course of allograft.
In keeping with this idea, elimination of B cells with anti-CD20
Ab in mice leads to two contrasting consequences on EAE progres-
sion, depending on the time course for B cell depletion. Depletion
of B cells before EAE induction exacerbates the severity of the
pathology whereas depletion during the acute phase decreases the
symptoms (81). Such a striking discrepancy is due to the fact that
early B cell depletion before EAE induction eliminates the Breg
cell population, and thus, their suppressive role in the disease. In
contrast, B cells depletion during the progression of EAE mainly
affects effector B cells, which prevents the activation of the CD4+
T cells, resulting in the downregulation of the disease severity. This
observation is linked to another study in which five patients out of
six who had received RTX as induction therapy, developed acute
rejection in the first 3 months after transplantation,compared with
patients who had received the anti-CD25 Ab Daclizumab (82).
Interestingly, patients who received RTX had a higher rate of acute
rejection compared to the control group, and also compared to
patients who did not received induction therapy. These findings
strictly emphasize the importance of B cell-targeting therapeutics
and time course of treatments. The balance between effector B
cells that promote immunity and Breg cells with potent immuno-
suppressive role, is a key factor in the microenvironment (83).
It becomes evident to considerate not only the time course of
the treatments but also to identify the relative contribution of
each B cell subset in the evolution of the disease for the develop-
ment of suitable therapeutic strategies. This is especially important
in transplantations where B cell depletion can lead to damaging
effects on the transplant (84)
PERSPECTIVES IN TRANSPLANTATION
B cells are crucial regulators of the immunity and their apti-
tude to generate and maintain tolerance should be exploited
for future immunotherapeutic advances in transplantation. Sev-
eral studies have analyzed the phenotype of circulating T lym-
phocyte subsets before and after transplantation to evaluate the
immunosuppressive effect of conventional treatments. Although
the reduction of CD4+ and CD8+ T cells and the augmentation of
CD4+CD25+Foxp3+ Treg cells have been described, there are still
conflicting data. Thus, the percentage of CD4+CD25+CD127low
circulatory Treg population is decreasing for years after transplan-
tation despite continuation of the immunosuppressive treatment.
In contrast, informations related to B cells are scarce. A decrease
of circulating B cell counts after transplantation has been elicited,
but the effects of this depletion on graft survival remain unclear
(85). However, it is likely that changes in lymphocyte subsets
might contribute to the rejection. To this end, analyses of the
B cell subsets distribution could be informative to provide an
overview of the immune reaction in case of rejection. Recent cel-
lular analyses showed an enrichment of naive and transitional B
cells but not of memory B cells in the peripheral blood of tolerant
patients without immunosuppressive treatment, compared with
immunosuppressed patients with stable graft function (86). We
also recently observed decreased frequencies and absolute num-
bers of activated and transitional B cells but elevated frequencies
and absolute numbers of memory B cells in patients with chronic
Ab-mediated rejection compared to patients with stable graft func-
tion (64). It will be of interest to know which B cell populations
are functionally defective in patients with graft rejection and, from
a prospective point of view to develop new therapeutics, to have a
rigorous follow-up of these populations in transplanted patients
before and after grafts.
An alternate method to improve tolerance in transplantation
would be to modulate B cell activation. However, the prevention
of antigen-specific B cell activation requires the identification of
the antigen responsible for BCR stimulation. The blockade of cos-
timulatory receptors like CD19 or CD21, or the stimulation of
inhibitory receptors such as CD22 could help achieve beneficial
effects through the inhibition of B cell responses. In this context,
the humanized anti-CD22 monoclonal Ab, Epratuzumab, has been
successfully used in the treatment of SLE. It succeeds in depleting
35% of total B cells while managing to inhibit B cell activation and
proliferation (87).
The induction and maintenance of tolerance, based on cellular
depletion or on the inhibition of cellular activation, appear to be
the most evident B cell-dependent approaches in transplantation.
However, it seems relevant now to develop new strategies to trigger
the expansion of the Breg population and maintain, or develop,
immune tolerance. One possibility could be the in vivo genera-
tion of Breg cells through the injection of a drug to induce the
activation signals for Breg cell differentiation in patients during
the transplantation. Yet, more knowledge on the development of
Breg cells has to be acquired. An alternative procedure would be
the in vitro generation of Breg cells, before their transfer into the
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receiver to elicit efficient regulatory functions. CD40 stimulation
could help expand IL-10-secreting positive B cells, which could
play an important immunosuppressive role. However, the con-
comitant activation of effector B cells may oppose the beneficial
effects of induced Breg cells. Another possibility to expand Bregs
has been recently proposed. The intravenous infusion of apoptotic
cells has been shown to prevent arthritis in mice. Activated splenic
B cells responded directly to apoptotic cells through the induc-
tion of Bregs, which resulted in the generation of IL-10-producing
Tregs (30). Consequently, mice were protected from severe joint
inflammation and bone destruction. Interestingly, the enhance-
ment of the production of IL-10 was abrogated in the absence of
natural IgM (88). Finally, developing therapeutic strategies that
exploit Bregs could be key to achieve tolerance in transplantation.
CONCLUSION
Diverse mechanisms are involved in graft tolerance but the genera-
tion of efficient Breg cells is undoubtedly one of the major aspects.
Thus, the rising role of Breg cells, specifically in graft rejection,
is now emerging in the current literature. Although our compre-
hension of animal models is getting more and more accurate, its
translation to humans is proving tricky. Many decisive questions
on Breg cell biology still need to be addressed. How can their
development be controlled? How can their function be induced?
Nevertheless, the discovery of Breg cells offers promising and inno-
vative therapeutic approaches, and this area is worthy of pursuit
in the near future.
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